	US 11,951,156 B2
	Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor
Paul B. Yu, Boston, MA (US); Asya Grinberg, Lexington, MA (US); Dianne S. Sako, Medford, MA (US); Roselyne Castonguay, Malden, MA (US); Rita Steeves, Stoneham, MA (US); and Ravindra Kumar, Acton, MA (US)
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US); and ACCELERON PHARMA, INC., Cambridge, MA (US)
Filed by THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US); and ACCELERON PHARMA, INC., Cambridge, MA (US)
Filed on Apr. 17, 2020, as Appl. No. 16/851,287.
Application 16/851,287 is a continuation of application No. 15/037,852, granted, now 10,682,392, previously published as PCT/US2014/066776, filed on Nov. 21, 2014.
Claims priority of provisional application 61/907,260, filed on Nov. 21, 2013.
Prior Publication US 2020/0323955 A1, Oct. 15, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); C07K 14/71 (2006.01); C07K 19/00 (2006.01)

CPC A61K 38/179 (2013.01) [A61K 47/6811 (2017.08); A61P 9/12 (2018.01); C07K 14/71 (2013.01); C07K 19/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)]

17 Claims

1. A method of treating, preventing, or reducing the progression rate of pulmonary hypertension (PH) in a subject, comprising administering to a subject in need thereof a polypeptide comprising a transforming growth factor-β (TGF-β) ligand binding domain of a TGF-β type II receptor and an Fc domain of an immunoglobulin, wherein the TGF-β ligand binding domain comprises the amino acid sequence as set forth in SEQ ID NO: 63.